GSK shares rise sharply after it settles $2.2bn Zantac lawsuits
The surprise settlement by GSK of the vast majority of Zantac lawsuits in the United States has removed a “major overhang” over the drugs company’s share price and resulted in a relief rally. The FTSE 100 company rose as much as 6.6 per cent on the London …